Iveda Solutions Launches $2 Million Public Offering With Series X Warrants

Reuters
Feb 10
Iveda Solutions Launches $2 Million Public Offering With Series X Warrants

Iveda Solutions Inc. has announced the pricing of a public offering consisting of 5,714,286 shares of its common stock (or pre-funded warrants in lieu thereof) and series X warrants to purchase up to 11,428,572 shares of its common stock. The combined public offering price is $0.35 per share (or pre-funded warrant in lieu thereof) and accompanying series X warrants. The series X warrants are exercisable immediately at a price of $0.35 per share and will expire two years from the date of issuance. The offering is expected to close on or about February 11, 2026, subject to customary closing conditions. The gross proceeds to Iveda are expected to be approximately $2.0 million before deducting fees and expenses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iveda Solutions Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9651684) on February 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10